Ligand To Acquire XOMA Royalty, Expanding Its Biopharma Royalty Portfolio

Ligand Pharmaceuticals agreed to acquire XOMA Royalty for $39.00 per share in cash, valuing the deal at approximately $739 million. The transaction significantly expands Ligand’s royalty portfolio and strengthens its position in the healthcare royalty space. This is a major strategic M&A move that should be supportive for Ligand’s long-term business profile.

Analysis

Ligand Pharmaceuticals agreed to acquire XOMA Royalty for $39.00 per share in cash, valuing the deal at approximately $739 million. The transaction significantly expands Ligand’s royalty portfolio and strengthens its position in the healthcare royalty space. This is a major strategic M&A move that should be supportive for Ligand’s long-term business profile.